FLGT SEC-arkiveringar - Fulgent Genetics, Inc.- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

LEI	549300CL6P01M68QJ404
CIK	1674930

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Fulgent Genetics, Inc.

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

June 2, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2026 FULGENT GENETICS, IN ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2026 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File
June 2, 2026	EX-99.1	Fulgent Presents Updated FID-007 Data at ASCO 2026 Exhibit 99.1 Fulgent Presents Updated FID-007 Data at ASCO 2026 EL MONTE, Calif.—June 1, 2026—Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 20
May 21, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2026 FULGENT GENETICS, IN ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2026 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File
May 21, 2026	EX-99.1	Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting Exhibit 99.1 Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting EL MONTE, Calif.—May 21, 2026—Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its
May 14, 2026	EX-10.1	FULGENT GENETICS, INC. 2026 EQUITY INCENTIVE PLAN Exhibit 10.1 FULGENT GENETICS, INC. 2026 EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Fulgent Genetics, Inc. 2026 Equity Incentive Plan, have the following meanings: “Administrator” means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the te
May 14, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 FULGENT GENETICS, IN ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File
May 14, 2026	EX-10.3	FULGENT GENETICS, INC. Stock Option Grant Notice Stock Option Grant under the Company’s 2026 Equity Incentive Plan Exhibit 10.3 Option No. FULGENT GENETICS, INC. Stock Option Grant Notice Stock Option Grant under the Company’s 2026 Equity Incentive Plan 1. Name and Address of Participant: 2. Grant Date: 3. Type of Grant: 4. Maximum Number of Shares for which this Option is exercisable: 5. Exercise (purchase) price per share: 6. Option Expiration Date: 7. Vesting Start Date: 8. Vesting Schedule: This Option sha
May 14, 2026	EX-FILING FEES	Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Fulgent Genetics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.0001 per share Other 3,500,000 $ 15.835 $ 55,422,500.00 0.0001381 $ 7,653.85 Total
May 14, 2026	EX-10.2	FULGENT GENETICS, INC. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Company’s 2026 Equity Incentive Plan Exhibit 10.2 Restricted Stock Unit No. FULGENT GENETICS, INC. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Company’s 2026 Equity Incentive Plan Name: Grant Number: Grant Date: Grant Type: Grant Shares: Vesting of Award: This Restricted Stock Unit Award shall vest as follows provided the Participant is an Employee, director or Consultant of the Company or of
May 14, 2026	S-8	As filed with the Securities and Exchange Commission on May 14, 2026 As filed with the Securities and Exchange Commission on May 14, 2026 Registration No.
May 1, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2026 FULGENT GENETICS, INC ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2026 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File N
May 1, 2026	EX-99.1	March 31, 2026 Exhibit 99.1 Fulgent Reports First Quarter 2026 Financial Results • Reiterates revenue guidance for fiscal year 2026 • Executed on stock repurchase program; purchased approximately 2.6 million shares in the first quarter of 2026 using $40.1 million in cash • Revenue of $71.1 million • GAAP gross profit of $21.5 million, or GAAP gross margin of 30.2%; Non-GAAP gross profit of $23.0 million, or Non-
May 1, 2026	EX-99.2	Founded in 2011 \| Located in El Monte, CA \| NASDAQ:FLGT Investor PresentationMay 1, 2026 Founded in 2011 \| Located in El Monte, CA \| NASDAQ:FLGT Investor Presentation May 1, 2026 Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc.
May 1, 2026	EX-10.2	ASSIGNMENT AND ASSUMPTION OF LEASE Exhibit 10.2 ASSIGNMENT AND ASSUMPTION OF LEASE This Assignment and Assumption of Lease (“Assignment”) is made as of March 16, 2026 (“Effective Date”), by and between Bakotic Pathology Associates, L.L.C., as assignor (“Assignor”), and Inform Diagnostics, Inc., a Delaware corporation, as assignee (“Assignee”). RECITALS A. Greenleaf Investment Partners L060, LLC, as Landlord (“Landlord”), and Assign
May 1, 2026	EX-10.1	COMMERCIAL LEASE AGREEMENT Exhibit 10.1 CERTAIN PERSONAL INFORMATION IN THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K. REDACTED PORTIONS ARE INDICATED WITH THE NOTATION “[***]”. COMMERCIAL LEASE AGREEMENT THIS LEASE is made this 21st day July, 2015 by and among BH Georgia Properties, LLC (“Landlord”) and Bakotic Pathology Associates, LLC (“Tenant”). WITHNESSETH: 1. PREMISES. Landlord, for and i
May 1, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC.
March 31, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 31, 2026	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) շ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ն TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37894 FULGENT GENETIC
March 31, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
March 17, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2026 FULGENT GENETICS, ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2026 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil
March 17, 2026	EX-99.1	Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx Exhibit 99.1 Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx EL MONTE, Calif.—March 17, 2026—Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced the completion of the acquisition of Bako Diagnostics, a premier pathology laboratory, and Strat
February 27, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37894 FULGENT GENETIC
February 27, 2026	EX-21.1	SUBSIDIARIES OF FULGENT GENETICS, INC. Exhibit 21.1 SUBSIDIARIES OF FULGENT GENETICS, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Fulgent Therapeutics LLC California Fulgent Investment Development Limited Hong Kong Cytometry Specialists, Inc. Georgia Inform Diagnostics, Inc Delaware Fulgent Pharma Holdings, Inc. Delaware Fulgent Australia Pty Ltd Australia ANP Technologies, Inc. Delaware
February 27, 2026	EX-99.1	December 31, 2025 Exhibit 99.1 Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results • Revenue of $83.3 million, growing 9% year-over-year • GAAP gross profit of $32.6 million, or GAAP gross margin of 39.1%; Non-GAAP gross profit of $34.2 million, or Non-GAAP gross margin of 41.0% • GAAP loss of $23.4 million, or ($0.76) per share; Non-GAAP income of $5.2 million, or $0.16 per share • Ended the year w
February 27, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2026 FULGENT GENETIC ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2026 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission
February 27, 2026	EX-99.2	Founded in 2011 \| Located in El Monte, CA \| NASDAQ:FLGT Investor PresentationFebruary 27, 2026 Founded in 2011 \| Located in El Monte, CA \| NASDAQ:FLGT Investor Presentation February 27, 2026 Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc.
December 22, 2025	EX-99.1	Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base Exhibit 99.1 Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base EL MONTE, Calif.— December 22, 2025—Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, tod
December 22, 2025	EX-10.1	Article I. DEFINITIONS Article II. PURCHASE AND SALE OF THE COMPANY INTERESTS Article III. REPRESENTATIONS AND WARRANTIES REGARDING THE COMPANY ENTITIES Article IV. REPRESENTATIONS AND WARRANTIES REGARDING SELLER Article V. REPRESENTATIONS AND WARRAN Exhibit 10.1 PURCHASE AND SALE AGREEMENT by and among BAKO PATHOLOGY LP, as Parent, BAKO PATHOLOGY HOLDINGS CORP., as Holdings, BPA HOLDING CORP., as Seller, DERMATOPATHOLOGY EXPERTS, LLC, as the Company, FULGENT THERAPEUTICS, LLC, as Buyer Parent (solely for purposes of ‎Section 11.16 (and ‎Article XI as it relates to ‎Section 11.16)), and INFORM DIAGNOSTICS, INC., as Buyer Dated as of December 2
December 22, 2025	EX-10.2	ASSET PURCHASE AGREEMENT by and among BAKO PATHOLOGY LP, BAKO PATHOLOGY HOLDINGS CORP., BPA HOLDING CORP., BAKOTIC PATHOLOGY ASSOCIATES, L.L.C., PODCEUTICALS L.L.C., GBRL CONSULTING, LLC, FULGENT THERAPEUTICS, LLC, INFORM DIAGNOSTICS, INC. Dated as o Exhibit 10.2 ASSET PURCHASE AGREEMENT by and among BAKO PATHOLOGY LP, BAKO PATHOLOGY HOLDINGS CORP., BPA HOLDING CORP., BAKOTIC PATHOLOGY ASSOCIATES, L.L.C., PODCEUTICALS L.L.C., GBRL CONSULTING, LLC, FULGENT THERAPEUTICS, LLC, and INFORM DIAGNOSTICS, INC. Dated as of December 20, 2025 TABLE OF CONTENTS Page ARTICLE I Definitions 1 Section 1.01 Certain Definitions 1 Section 1.02 Terms Generally. 1
December 22, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2025 FULGENT GENETIC ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2025 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission
November 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2025 FULGENT GENETICS ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2025 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission F
November 7, 2025	EX-99.2	Founded in 2011 \| Located in El Monte, CA \| NASDAQ:FLGT Investor PresentationNovember 7, 2025 Founded in 2011 \| Located in El Monte, CA \| NASDAQ:FLGT Investor Presentation November 7, 2025 Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc.
November 7, 2025	EX-99.1	September 30, 2025 Exhibit 99.1 Fulgent Reports Third Quarter 2025 Financial Results • Revenue of $84.1 million, growing 17% year-over-year • Raising Full Year 2025 Revenue Guidance to $325.0 million • Raising Full Year 2025 EPS Guidance to GAAP loss of approximately ($1.70) per share and Non-GAAP income of $0.30 per share • GAAP gross profit of $35.5 million, or GAAP gross margin of 42.2%; Non-GAAP gross profit of
November 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC.
October 20, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2025 FULGENT GENETICS ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2025 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission F
October 20, 2025	EX-99.1	Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference Exhibit 99.1 Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference EL MONTE, CA, October 20, 2025 — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced preliminary clinical data as of September 25, 2025, the preliminary d
September 3, 2025	144	144 144 0001819718 XXXXXXXX LIVE 0001674930 FULGENT GENETICS, INC. 001-37894 4399 Santa Anita Ave El Monte CA 91731 626-350-0537 Xie Jian Officer Common Stock Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th FL New York NY 10004 1128 24846.15 30609044 09/03/2025 NASDAQ Common Stock 02/28/2022 Resticted stock vest Fulgent Genetics, Inc. N 32000 02/28/2022 Equity compensation for services rendered
September 3, 2025	144	144 144 0001684532 XXXXXXXX LIVE 0001674930 FULGENT GENETICS, INC. 001-37894 4399 Santa Anita Ave El Monte CA 91731 626-350-0537 Gao Hanlin Officer Common Stock Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th FL New York NY 10004 1063 23414.42 30609044 09/03/2025 NASDAQ Common Stock 02/28/2022 Restricted stock vest Fulgent Genetics, Inc. N 32000 02/28/2022 Equity compensation for services rende
August 27, 2025	144/A	144/A 144/A 0000950170-25-080335 0001819718 XXXXXXXX LIVE 0001674930 FULGENT GENETICS, INC.
August 27, 2025	144	144 144 0001819718 XXXXXXXX LIVE 0001674930 FULGENT GENETICS, INC. 001-37894 4399 Santa Anita Ave El Monte CA 91731 626-350-0537 Xie Jian Officer Common Stock Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th FL New York NY 10004 1199 25760.2 30609044 08/27/2025 NASDAQ Common Stock 02/26/2024 Resticted stock vest Fulgent Genetics, Inc. N 25350 02/26/2024 Equity compensation for services rendered
August 27, 2025	144/A	144/A 144/A 0001819718-25-000005 0001819718 XXXXXXXX LIVE 0001674930 FULGENT GENETICS, INC.
August 27, 2025	144	144 144 0001684532 XXXXXXXX LIVE 0001674930 FULGENT GENETICS, INC. 001-37894 4399 Santa Anita Ave El Monte CA 91731 626-350-0537 Gao Hanlin Officer Common Stock Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th FL New York NY 10004 943 20260.11 30609044 08/27/2025 NASDAQ Common Stock 02/26/2024 Restricted stock vest Fulgent Genetics, Inc. N 21146 02/26/2024 Equity compensation for services render
August 1, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 FULGENT GENETICS, ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil
August 1, 2025	EX-99.1	June 30, 2025 Exhibit 99.1 Fulgent Reports Second Quarter 2025 Financial Results • Core Revenue of $81.7 million grows 16% year-over-year • Raising Full Year 2025 Core Revenue Guidance to $320 million • GAAP gross profit of $34.4 million, or GAAP gross margin of 42.1%; Non-GAAP gross profit of $36.2 million, or Non-GAAP gross margin of 44.2% • GAAP loss of $19.0 million, or ($0.62) per share, inclusive of a one
August 1, 2025	EX-99.2	Founded in 2011 \| Located in El Monte, CA \| NASDAQ:FLGT Investor Presentation August 1, 2025 Founded in 2011 \| Located in El Monte, CA \| NASDAQ:FLGT Investor Presentation August 1, 2025 Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc.
August 1, 2025	10-Q	f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC.
May 15, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 FULGENT GENETICS, IN ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File
May 2, 2025	EX-10.1	Amended and Restated Director Compensation Program Exhibit 10.1 FULGENT GENETICS, INC. AMENDED AND RESTATED DIRECTOR COMPENSATION PROGRAM This Amended and Restated Director Compensation Program (this “Program”) sets forth the compensation payable to directors of Fulgent Genetics, Inc., a Delaware corporation (the “Company”), as consideration for their service as directors of the Company. This Program does not constitute a legally binding contract
May 2, 2025	10-Q	f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC.
May 2, 2025	EX-99.2	Founded in 2011 \| Located in El Monte, CA \| NASDAQ:FLGT Investor Presentation May 2, 2025 Founded in 2011 \| Located in El Monte, CA \| NASDAQ:FLGT Investor Presentation May 2, 2025 Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc.
May 2, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2025 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File N
May 2, 2025	EX-99.1	March 31, 2025 Exhibit 99.1 Fulgent Reports First Quarter 2025 Financial Results • Core Revenue of $73.5 million grows 16% year-over-year • Reiterating Full Year 2025 Core Revenue Guidance of $310 million • Non-GAAP income of $1.2 million, or $0.04 per share; GAAP loss of $11.5 million, or ($0.37) per share • Ended Q1 with $814.6 million of cash, cash equivalents, restricted cash, and investments in marketable s
March 26, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 26, 2025	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37894 FULGENT GENETIC
March 25, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
February 28, 2025	EX-99.2	Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the “ Founded in 2011 \| Located in El Monte, CA \| NASDAQ:FLGT Investor Presentation February 28, 2025 Exhibit 99.
February 28, 2025	EX-4.2	Description of the registrant’s securities. Exhibit 4.2 DESCRIPTION OF FULGENT GENETICS, INC.’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Fulgent Genetics, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act: common stock, $0.0001 par value per share, or Common Stock. Unless the context otherwise requires, all reference
February 28, 2025	EX-99.1	December 31, 2024 Exhibit 99.1 Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results • Full Year Total Revenue of $283.5 million • Full Year Core Revenue grows 7% year-over-year to $281.2 million • Ended 2024 with $828.6 million of cash, cash equivalents, restricted cash, and investments in marketable securities, representing cash per share of $26.87 EL MONTE, CA, February 28, 2025 — Fulgent Genetics,
February 28, 2025	EX-21.1	Subsidiaries of the registrant. Exhibit 21.1 SUBSIDIARIES OF FULGENT GENETICS, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Fulgent Therapeutics LLC California Fulgent Investment Development Limited Hong Kong Cytometry Specialists, Inc. Georgia Inform Diagnostics, Inc Delaware Fulgent Pharma Holdings, Inc. Delaware Fulgent Australia Pty Ltd Australia
February 28, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37894 FULGENT GENETIC
February 28, 2025	EX-19.1	Insider Trading Policy Exhibit 19.1 FULGENT GENETICS, INC. INSIDER TRADING POLICY Adopted: September 16, 2016 Last Revised and Approved: February 26, 2024 This Insider Trading Policy (“Policy”) provides guidelines concerning transactions in the securities of Fulgent Genetics, Inc. (“Company”) and the handling of confidential information about the Company and the companies with which the Company does business. The Compan
February 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 FULGENT GENETIC ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission
January 8, 2025	EX-99.1	JOINT FILING AGREEMENT EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.
November 8, 2024	EX-99.1	September 30, 2024 Exhibit 99.1 Fulgent Reports Third Quarter 2024 Financial Results • Total Revenue of $71.7 million • Core Revenue grows 9% year-over-year to $71.7 million • Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 EL MONTE, CA, November 8, 2024 — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company wit
November 8, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission F
November 8, 2024	EX-99.2	Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the “ Founded in 2011 \| Located in El Monte, CA \| NASDAQ:FLGT Investor Presentation November 8, 2024 Exhibit 99.
November 8, 2024	10-Q	f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC.
November 5, 2024	SC 13D/A	FLGT / Fulgent Genetics, Inc. / Hsieh Ming - SC 13D/A Activist Investment SC 13D/A 1 sc13da-minghsieh11524.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3) Fulgent Genetics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 359664109 (CUSIP Number) Ming Hsieh c/o Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Mont
August 2, 2024	EX-99.2	Founded in 2011 \| Located in El Monte, CA \| NASDAQ:FLGT Investor Presentation August 2, 2024 Founded in 2011 \| Located in El Monte, CA \| NASDAQ:FLGT Investor Presentation August 2, 2024 Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc.
August 2, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2024 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil
August 2, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC.
August 2, 2024	EX-99.1	June 30, 2024 Exhibit 99.1 Fulgent Reports Second Quarter 2024 Financial Results • Total Revenue of $71.0 million • Core Revenue grows 5% year-over-year to $70.2 million • Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 EL MONTE, CA, August 2, 2024 — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with
May 16, 2024	8-K	Submission of Matters to a Vote of Security Holders ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File
May 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 FULGENT GENETICS, INC ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File N
May 3, 2024	EX-99.2	Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the “ Founded in 2011 \| Located in El Monte, CA \| NASDAQ:FLGT Investor Presentation May 3, 2024 Exhibit 99.
May 3, 2024	EX-99.1	March 31, Exhibit 99.1 Fulgent Reports First Quarter 2024 Financial Results • Total Revenue of $64.5 million • Core Revenue grows 1% year-over-year to $63.2 million • Reiterates Full Year 2024 Core Revenue Guidance of $280 million EL MONTE, CA, May 3, 2024 — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business an
May 3, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC.
March 27, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 27, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
February 28, 2024	EX-4.2	Description of the registrant’s securities. Exhibit 4.2 DESCRIPTION OF FULGENT GENETICS, INC.’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2023, Fulgent Genetics, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act: common stock, $0.0001 par value per share, or Common Stock. Unless the context otherwis
February 28, 2024	EX-21.1	Subsidiaries of the registrant. Exhibit 21.1 SUBSIDIARIES OF FULGENT GENETICS, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Fulgent Therapeutics LLC California Fulgent Investment Development Limited Hong Kong Cytometry Specialists, Inc. Georgia Inform Diagnostics, Inc Delaware Fulgent Pharma Holdings, Inc. Delaware
February 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 FULGENT GENETIC ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission
February 28, 2024	EX-99.1	December 31, Exhibit 99.1 Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results • Full Year 2023 Total Revenue of $289.2 million; Q4 2023 Total Revenue of $70.5 million • Full Year 2023 Core Revenue grows 44% year-over-year to $262.1 million; Q4 2023 Core Revenue grows 21% year-over-year to $66.5 million • Ended 2023 with $847.7 million of cash, cash equivalents, and investments in marketable sec
February 28, 2024	EX-10.41	Rule 10b5-1 Issuer Repurchase Plan, by and between Fulgent Genetics, Inc. and Piper Sandler & Co., dated December 12, 2023 Exhibit 10.41 Rule 10b5-1 Issuer Repurchase Plan This Rule 10b5-1 Issuer Repurchase Plan (this “Plan”) is entered into this 12th day of December, 2023 between Fulgent Genetics, Inc. (“Company”) and Piper Sandler & Co. (“Broker”). Recitals Whereas, Company desires to establish this Plan to systematically repurchase shares of its common stock, par value $0.0001 per share (the “Shares”) in accordance
February 28, 2024	EX-99.2	Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (“Fulg Founded in 2011 \| Located in El Monte, CA \| NASDAQ:FLGT Investor Presentation February 28, 2024 Exhibit 99.
February 28, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37894 FULGENT GENETIC
February 8, 2024	LETTER	LETTER United States securities and exchange commission logo February 8, 2024 Paul Kim Chief Financial Officer Fulgent Genetics, Inc.
February 7, 2024	CORRESP	February 7, 2024 3580 Camel Mountain Road Suite 300 San Diego, CA 92130 858 314 1500 mintz.com February 7, 2024 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Attn: Tracey Houser Terence O’Brien Re: Fulgent Genetics, Inc. Form 10-K for Fiscal Year Ended December 31, 2022 Form 10
January 30, 2024	LETTER	LETTER United States securities and exchange commission logo January 30, 2024 Paul Kim Chief Financial Officer Fulgent Genetics, Inc.
January 23, 2024	SC 13G/A	FLGT / Fulgent Genetics, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us3596641098012324.txt us3596641098012324.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) Fulgent Genetics, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 359664109 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate
January 9, 2024	CORRESP	* * * 3580 Camel Mountain Road Suite 300 San Diego, CA 92130 858 314 1500 mintz.com January 9, 2024 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Attn: Tracey Houser Terence O’Brien Re: Fulgent Genetics, Inc. Form 10-K for Fiscal Year Ended December 31, 2022 Filed Fe
November 21, 2023	LETTER	LETTER United States securities and exchange commission logo November 21, 2023 Paul Kim Chief Financial Officer Fulgent Genetics, Inc.
November 14, 2023	CORRESP	November 14, 2023 3580 Camel Mountain Road Suite 300 San Diego, CA 92130 858 314 1500 mintz.com November 14, 2023 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Attn: Tracey Houser Terence O’Brien Re: Fulgent Genetics, Inc. Form 10-K for Fiscal Year Ended December 31, 2022 Filed
November 3, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission F
November 3, 2023	EX-10.2	Amended and Restated Executive Officer Incentive Plan Exhibit 10.2 Fulgent Genetics, Inc. Amended and Restated Executive Officer Incentive Plan Effective October 30, 2023 Introduction The Amended and Restated Executive Officer Incentive Plan (the “Plan”) is an annual incentive compensation program designed to support the pay for performance philosophy of Fulgent Genetics, Inc. (“Company”) by rewarding members of the executive management team for thei
November 3, 2023	EX-10.1	Amended and Restated Incentive Compensation Recoupment Policy Exhibit 10.1 FULGENT GENETICS, INC. AMENDED AND RESTATED INCENTIVE COMPENSATION RECOUPMENT POLICY I. Introduction The Compensation Committee of the Board of Directors (the “Committee”) of Fulgent Genetics, Inc. (the “Company”) believes it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces th
November 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC.
November 3, 2023	EX-99.2	Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the “ Founded in 2011 \| Located in Los Angeles, CA \| NASDAQ:FLGT Investor Presentation November 3, 2023 Exhibit 99.
November 3, 2023	EX-99.1	September 30, Exhibit 99.1 Fulgent Reports Third Quarter 2023 Financial Results • Core Revenue of $66 million represents Growth of 17% Year-over-Year • Additional Reimbursement from COVID-19 Test Sales yields Revenue of $19 million, for Total Revenue of $85 million • Reiterates Full Year 2023 Core Revenue Guidance of $260 million EL MONTE, CA, November 3, 2023 — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”
November 1, 2023	LETTER	LETTER United States securities and exchange commission logo November 1, 2023 Paul Kim Chief Financial Officer Fulgent Genetics, Inc.
August 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC.
August 4, 2023	EX-99.2	Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the “ Founded in 2011 \| Located in Los Angeles, CA \| NASDAQ:FLGT Investor Presentation August 4, 2023 Exhibit 99.
August 4, 2023	EX-99.1	June 30, Exhibit 99.1 Fulgent Reports Second Quarter 2023 Financial Results • Total Revenue of $68 million • Record Core Revenue of $67 million, growth of 48% year-over-year • Raises Full Year 2023 Core Revenue Guidance to $260 million and Narrows Expected Loss EL MONTE, CA, August 4, 2023 — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-establish
August 4, 2023	EX-3.2	Amended and Restated Bylaws of the registrant. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF FULGENT GENETICS, INC. a Delaware Corporation TABLE OF CONTENTS Page ARTICLE 1 OFFICES 1 Section 1.1 Registered Office. 1 Section 1.2 Other Offices. 1 ARTICLE 2 STOCKHOLDERS’ MEETINGS 1 Section 2.1 Place of Meetings. 1 Section 2.2 Annual Meetings. 2 Section 2.3 Special Meetings. 2 Section 2.4 Notice of Meetings. 2 Section 2.5 Quorum and Voting. 3 Section
August 4, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil
May 18, 2023	S-8	As filed with the Securities and Exchange Commission on May 18, 2023 As filed with the Securities and Exchange Commission on May 18, 2023 Registration No.
May 18, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File
May 18, 2023	EX-FILING FEES	Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Fulgent Genetics, Inc.
May 18, 2023	EX-10.1	Amended and Restated 2016 Omnibus Incentive Plan of the registrant Exhibit 10.1 FULGENT GENETICS, INC. AMENDED AND RESTATED 2016 OMNIBUS INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. 2. Definitions. The following definitions shall apply as used herein and in the i
May 5, 2023	EX-10	Amended and Restated Non-Employee Director Compensation Policy, dated as of February 23, 2023. Exhibit 10.1 FULGENT GENETICS, INC. AMENDED AND RESTATED DIRECTOR COMPENSATION PROGRAM This Amended and Restated Director Compensation Program (this “Program”) sets forth the compensation payable to directors of Fulgent Genetics, Inc., a Delaware corporation (the “Company”), as consideration for their service as directors of the Company. This Program does not constitute a legally binding contract
May 5, 2023	EX-99	Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the “ Founded in 2011 \| Located in Los Angeles, CA \| NASDAQ:FLGT Investor Presentation May 5, 2023 Exhibit 99.
May 5, 2023	EX-10	Executive Officer Incentive Plan Exhibit 10.3 Fulgent Genetics, Inc. Executive Officer Incentive Plan Effective January 1, 2023 Introduction The Executive Officer Incentive Plan (the “Plan”) is an annual incentive compensation program designed to support the pay for performance philosophy of Fulgent Genetics, Inc. (“Company”) by rewarding members of the executive management team for their contributions in the achievement of corpo
May 5, 2023	EX-99	March 31, Exhibit 99.1 Fulgent Reports First Quarter 2023 Financial Results • Total Revenue of $66.2 million • Record Core Revenue of $62.7 million, growth of 150% year-over-year • Raises Full Year 2023 Core Revenue Guidance to $250 million EL MONTE, CA, May 5, 2023 — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic bu
May 5, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC.
May 5, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2023 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File N
April 3, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A 1 flgt2023defa14asuppl.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only
March 31, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 31, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
February 28, 2023	EX-10	2022 Fulgent Pharma Holdings, Inc. Omnibus Incentive Plan Exhibit 10.52 FULGENT PHARMA HOLDINGS, INC. 2022 OMNIBUS INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. 2. Definitions. The following definitions shall apply as used herein and in the individual Awa
February 28, 2023	S-8	As filed with the Securities and Exchange Commission on February 28, 2023 S-8 1 flgts-82023.htm S-8 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-2621304 (State or other jurisdiction of incorporati
February 28, 2023	EX-10	Commercial Lease Amendment (I), dated December 30, 2013, by and between Inform Diagnostics, Inc. and LC Med Property TT, LLC EXHIBIT 10.49 FIRST AMENDMENT AND PARTIAL RESTATEMENT OF LEASE THIS First Amendment and Partial Restatement of Lease (this “Amendment”) is entered into as of December 30, 2013 (the “Effective Date”), between LC MED PROPERTY TT, LLC, a Delaware limited liability company (“Landlord”), successor-in-interest to iStar CTL I, L.P. (“Original Landlord”), and MIRACA LIFE SCIENCES, INC., a Delaware corpora
February 28, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37894 FULGENT GENETIC
February 28, 2023	EX-FILING FEES	Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Fulgent Genetics, Inc.
February 28, 2023	EX-99	Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the “ Founded in 2011 \| Located in Los Angeles, CA \| NASDAQ:FLGT Investor Presentation February 28, 2023 Exhibit 99.
February 28, 2023	EX-10	Commercial Lease Agreement, dated October 20, 2008, by and between Inform Diagnostics, Inc. and iSTAR CTL I, L.P. Exhibit 10.48 SECOND AMENDMENT TO LEASE AGREEMENT THIS SECOND AMENDMENT TO LEASE AGREEMENT (this "Second Amendment") dated and effective for reference purposes as of July 1, 2020, is made by and between WPT LAND 2 LP, a Delaware limited partnership ("Landlord), and INFORM DIAGNOSTICS, INC., a Delaware corporation ("Tenant). BACKGROUND: A. Landlord (as successor in interest to Liberty Property Limi
February 28, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission
February 28, 2023	EX-10	Commercial Lease Amendment (II), dated February 3, 2014, by and between Inform Diagnostics, Inc. and LC Med Property TT, LLC Exhibit 10.50 SECOND AMENDMENT TO LEASE THIS Second Amendment to Lease (this “Amendment”) is entered into as of February 3, 2014 (the “Effective Date”), between LC MED PROPERTY TT, LLC , a Delaware limited liability company (“Landlord”), successor-in-interest to iStar CTL I, L.P. (“Original Landlord”), and MIRACA LIFE SCIENCES, INC., a Delaware corporation (“Tenant”), successor-in interest to Cari
February 28, 2023	EX-21	Subsidiaries of the registrant. Exhibit 21.1 SUBSIDIARIES OF FULGENT GENETICS, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Fulgent Therapeutics LLC California Fulgent Investment Development Limited Hong Kong Cytometry Specialists, Inc. Georgia Inform Diagnostics, Inc Delaware Fulgent Pharma Holdings, Inc. Delaware
February 28, 2023	EX-10	Commercial Lease Agreement by and between Inform Diagnostics and Crawford Street DE, LLC Exhibit 10.51 LEASE OF PREMISES AT 15-19 CRAWFORD STREET NEEDHAM, MASSACHUSETTS FROM CRAWFORD STREET DE, LLC TO MIRACA LIFE SCIENCES, INC. TABLE OF CONTENTS Page SUMMARY OF BASIC TERMS iii ARTICLE I 1 ARTICLE II 5 Section 2.1 Lease Of The Premises 5 Section 2.2 Common Rights 5 Section 2.3 Parking 5 Section 2.4 Lease Term 6 Section 2.5 Security Deposit 6 Section 2.6 Lease Amendment 8 Section 2.6 Ri
February 28, 2023	EX-99	December 31, Exhibit 99.1 Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results • Full Year 2022 Total Revenue of $619.0 million; Q4 Total Revenue of $67.7 million • Full Year 2022 Core Revenue grows 95% year-over-year to $181.5 million; Q4 Core Revenue grows 97% year-over-year to $55.0 million TEMPLE CITY, CA, February 28, 2023 — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”, or the “Company”
February 28, 2023	EX-4	Description of the registrant’s securities. Exhibit 4.3 DESCRIPTION OF FULGENT GENETICS, INC.’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, Fulgent Genetics, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act: common stock, $0.0001 par value per share, or Common Stock. Unless the context otherwis
February 28, 2023	EX-10	Rule 10b5-1 Issuer Repurchase Plan, by and between Fulgent Genetics, Inc. and Piper Sandler & Co., dated December 15, 2022 Exhibit 10.46 Rule 10b5-1 Issuer Repurchase Plan This Rule 10b5-1 Issuer Repurchase Plan (this “Plan”) is entered into this 15th day of December, 2022 between Fulgent Genetics, Inc. (“Company”) and Piper Sandler & Co. (“Broker”). Recitals Whereas, Company desires to establish this Plan to systematically repurchase shares of its common stock, par value $0.0001 per share (the “Shares”) in accordance
January 26, 2023	SC 13G/A	FLGT / Fulgent Genetics Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us3596641098012623.txt us3596641098012623.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) FULGENT GENETICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 359664109 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate b
January 20, 2023	SC 13G	FLGT / Fulgent Genetics Inc / BlackRock Inc. Passive Investment SC 13G 1 us3596641098012023.txt us3596641098012023.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) FULGENT GENETICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 359664109 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box
January 12, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fi
January 12, 2023	EX-1.1	Commercial Lease Addendum (II) by and between Fulgent Therapeutics LLC and E&E Plaza LLC Exhibit 1.1 COMMERCIAL LEASE ADDENDUM (II) This LEASE ADDENDUM II to the Commercial Lease Agreement signed on February 1, 2018 by E&E Plaza LLC ("Lessor") and Fulgent Therapeutics LLC ("Lessee"). This document modifies the Commercial Lease Agreement as describe below: 1. The Lessor agrees to extend this lease for ONE (1) year, starting on February 1, 2023 and expiring on January 31, 2024. 2. For t
January 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 FULGENT GENETICS, ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fi
January 3, 2023	EX-99.1	Fulgent Expands Board of Directors with Addition of Reggie Groves Exhibit 99.1 Fulgent Expands Board of Directors with Addition of Reggie Groves TEMPLE CITY, California –January 3, 2023 – Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of Reggie Groves to its board of directors, effective January 3, 2023. “Reggie possesses a diverse business skill set and a global perspective that we believe wil
November 23, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2022 (November 18, 2022) FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorpo
November 10, 2022	EX-1	Joint Filing Agreement, dated as of December 22, 2020, by and among Mr. Hsieh and the Trust Exhibit 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements.
November 10, 2022	SC 13D/A	FLGT / Fulgent Genetics Inc / Hsieh Ming - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Fulgent Genetics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 359664109 (CUSIP Number) Ming Hsieh c/o Fulgent Genetics, Inc. 4978 Santa Anita Avenue Temple City, California 91780 (626) 350-0537 (Name, A
November 7, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 FULGENT GENETICS ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission F
November 7, 2022	EX-99.4	Ming Hsieh Chairman, CEO, Founder Founded in 2011 \| Located in Los Angeles, CA \| NASDAQ:FLGT Announces Third Quarter 2022 Earnings and Acquisition of Fulgent Pharma November 7, 2022 Exhibit 99.
November 7, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ff UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC.
November 7, 2022	EX-10.3	Agreement and Plan of Merger, by and among Fulgent Genetics, FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc. and solely for purposes of Section 2.4, Section 5.5, Article VI, Section 7.8 and Section 7.14, those company stockholders set forth on the signature page thereto, dated November 7, 2022 Exhibit 10.3 AGREEMENT AND PLAN OF Merger BY AND AMONG FULGENT GENETICS, INC., FG MERGER SUB, inc., FULGENT PHARMA HOLDINGS, INC., AND THE STOCKHOLDERS SET FORTH HEREIN NOVEMBER 7, 2022 TABLE OF CONTENTS Page Article I THE MERGER 1 1.1 Merger 1 1.2 Effective Time 2 1.3 Effects of the Merger 2 1.4 Closing 2 1.5 Closing Deliverables. 2 1.6 Certificate of Incorporation and Bylaws 3 1.7 Directors and
November 7, 2022	EX-10.1	Amended and Restated Non-Employee Director Compensation Policy, dated as of August 1, 2022. Exhibit 10.1 FULGENT GENETICS, INC. AMENDED AND RESTATED DIRECTOR COMPENSATION PROGRAM This Amended and Restated Director Compensation Program (this “Program”) sets forth the compensation payable to directors of Fulgent Genetics, Inc., a Delaware corporation (the “Company”), as consideration for their service as directors of the Company. This Program does not constitute a legally binding contract
November 7, 2022	EX-99.3	Mission, Core Values, and Strategy Mission Develop flexible and affordable genomic testing that improves the everyday lives of those around us Core Values Innovation Customer service and commitment Quality Efficiency Strategy Leverage our proprietary Founded in 2011 \| Located in Los Angeles, CA \| NASDAQ:FLGT Investor Presentation November 7, 2022 Exhibit 99.
November 7, 2022	EX-99.1	September 30, Exhibit 99.1 Fulgent Genetics Reports Third Quarter 2022 Financial Results • Revenue totals $105.7 million • Core Revenue grows 110% year-over-year to $56.0 million TEMPLE CITY, CA, November 7, 2022 —Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rar
November 7, 2022	EX-10.2	Form of Notice of Restricted Stock Unit Award and Restricted Stock Unit Agreement under the Fulgent Pharma Holdings, Inc. 2022 Omnibus Incentive Plan Exhibit 10.2 FULGENT PHARMA HOLDINGS, INC. 2022 OMNIBUS INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD You (the “Grantee”) have been granted an award of Restricted Stock Units (the “Award”), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the “Notice”), the Fulgent Pharma Holdings, Inc. 2022 Omnibus Incentive Plan, as amended from time to time (the “Plan”)
November 7, 2022	EX-99.2	Fulgent Genetics Acquires Fulgent Pharma, Creating a New Paradigm in Precision Medicine for The Company Fulgent Genetics aims to transform from a genomic diagnostic business into a fully integrated precision medicine company focused on oncology Fulge Exhibit 99.2 Fulgent Genetics Acquires Fulgent Pharma, Creating a New Paradigm in Precision Medicine for The Company Fulgent Genetics aims to transform from a genomic diagnostic business into a fully integrated precision medicine company focused on oncology Fulgent Pharma’s proprietary novel nano-drug delivery technology platform synergistically underpins the combined businesses, potentially provi
November 4, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission F
September 29, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission
August 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ff UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC.
August 4, 2022	EX-99.2	Mission, Core Values, and Strategy Mission Develop flexible and affordable genomic testing that improves the everyday lives of those around us Core Values Innovation Customer service and commitment Quality Efficiency Strategy Leverage our proprietary Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc.
August 4, 2022	EX-99.1	June 30, Exhibit 99.1 Fulgent Genetics Reports Second Quarter 2022 Financial Results ? Revenue totals $125.3 million ? Core Revenue grows 102% year-over-year to $45.3 million ? Raises full year core revenue outlook to $185 million from previously announced $180 million TEMPLE CITY, CA, August 4, 2022 ?Fulgent Genetics, Inc. (NASDAQ: FLGT) (?Fulgent Genetics?, ?Fulgent?, or the ?Company?), a technology-base
August 4, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil
June 30, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File
May 19, 2022	8-K	Submission of Matters to a Vote of Security Holders ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File
May 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ff UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC.
May 5, 2022	EX-99.1	Press Release Announcing Appointment Jian Xie Exhibit 99.1 Fulgent Genetics Announces Promotions and Leadership Updates TEMPLE CITY, CA, May 3, 2022 ?Fulgent Genetics, Inc. (NASDAQ: FLGT) (?Fulgent Genetics?, ?Fulgent?, or the ?Company?), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a number of promotions and appointments acr
May 3, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File N
May 3, 2022	EX-99.2	Mission, Core Values, and Strategy Mission Develop flexible and affordable genomic testing that improves the everyday lives of those around us Core Values Innovation Customer service and commitment Quality Efficiency Strategy Leverage our proprietary Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc.
May 3, 2022	EX-99.1	March 31, Exhibit 99.1 Fulgent Genetics Reports First Quarter 2022 Financial Results ? Revenue totals $320.3 million ? Core Revenue excluding COVID-19 NGS testing grows 59% year-over-year to $25.1 million ? Raises full year revenue outlook to $660 million from previously announced $600 million ? Raises full year core revenue outlook to $180 million from previously announced $175 million TEMPLE CITY, CA, May
April 26, 2022	EX-2.1	Agreement and Plan of Merger by and among Fulgent Therapeutics LLC, solely for purpose of Section 6.20, Fulgent Genetics, Inc., Ducks Acquisition Sub, Inc., Symphony Buyer, Inc., solely in its capacity as the representative of Symphony’s securityholders, Avista Capital Partners IV GP, L.P. and solely for purposes of Section 6.21, Article VIII and Section 10.14, those company stockholders set forth on the signature page thereto, dated as of April 16, 2022. EX-2.1 2 flgt-ex217.htm EX-2.1 Exhibit 2.1 STRICTLY CONFIDENTIAL AGREEMENT AND PLAN OF Merger BY AND AMONG FULGENT THERAPEUTICS LLC, DUCKS ACQUISITION SUB, INC., FULGENT GENETICS, INC., SYMPHONY BUYER, INC., SOLELY IN ITS CAPACITY AS THE Stockholder Representative, Avista Capital Partners IV GP, L.P., AND, SOLELY FOR PURPOSES OF SECTION 6.21, ARTICLE VIII AND SECTION 10.14, THOSE COMPANY STOCKHOLD
April 26, 2022	8-K	Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil
April 18, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil
April 18, 2022	EX-99.1	Fulgent Genetics Agrees to Acquire Inform Diagnostics and Provides Preliminary First Quarter Revenue Results Proposed acquisition will add diagnostic offerings, including hematopathology and anatomic pathology, while also providing a highly complemen Exhibit 99.1 Fulgent Genetics Agrees to Acquire Inform Diagnostics and Provides Preliminary First Quarter Revenue Results Proposed acquisition will add diagnostic offerings, including hematopathology and anatomic pathology, while also providing a highly complementary nationwide commercial infrastructure to support Fulgent?s rapidly expanding genomic testing footprint Preliminary first quarter reve
March 29, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 flgt-def14a20220518.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only
March 29, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil
March 29, 2022	EX-10.1	Fulgent Genetics, Inc. Incentive Compensation Recoupment Policy. EX-10.1 2 flgt-ex1017.htm EX-10.1 Exhibit 10.1 FULGENT GENETICS, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY Fulgent Genetics, Inc. has adopted this Incentive Compensation Recoupment Policy, which is effective as of March 28, 2022 (the “Effective Date”). 1.Certain Definitions. (a)“Board” means the Board of Directors of the Company. (b)“Committee” means the Compensation Committee of the Board. (c
February 28, 2022	EX-10.41	Amended and Restated Commercial Lease Agreement, dated May 6, 2016, by and between Store Master Funding IX, LLC and Cytometry Specialists, Inc. Exhibit 10.41 AMENDED AND RESTATED LEASE by and between STORE MASTER FUNDING IX, LLC as Landlord and CYTOMETRY SPECIALISTS, INC., as Tenant. May 6, 2016 4823-7309-7009.2 STORE / CSI Labs Amended and Restated Lease Agreement 2580 Westside Dr., Alpharetta, GA File No.: 7210/02-432.1 TABLE OF CONTENTS ARTICLE/SECTION PAGE NO. Article I LEASE OF PREMISES; POSSESSION 1 Section 1.1. Lease to Tenant 1 Se
February 28, 2022	EX-21.1	Subsidiaries of the registrant. Exhibit 21.1 SUBSIDIARIES OF FULGENT GENETICS, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Fulgent Therapeutics LLC California Fulgent Investment Development Limited Hong Kong Cytometry Specialists, Inc. Georgia
February 28, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K closed UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37894 FULGENT
February 23, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission
February 23, 2022	EX-99.1	December 31, Exhibit 99.1 Fulgent Genetics Reports Fourth Quarter and Full Year 2021 Financial Results ? Full Year 2021 Total Revenue grows 135% year-over-year to $992.6 million; Q4 Revenue totals $251.7 million ? Full Year 2021 Core Revenue grows 236% year-over-year to $122.6 million; Q4 Core Revenue grows 234% year-over-year to $40.1 million TEMPLE CITY, CA, February 23, 2022 ?Fulgent Genetics, Inc. (NASDAQ:
February 23, 2022	EX-99.2	Mission, Core Values, and Strategy 3 Mission Develop flexible and affordable genomic testing that improves the everyday lives of those around us Core Values Innovation Customer service and commitment Quality Efficiency Strategy Leverage our proprieta 1 Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc.
January 27, 2022	SC 13G/A	FLGT / Fulgent Genetics Inc / BlackRock Inc. Passive Investment us3596641098012722.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) FULGENT GENETICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 359664109 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
January 26, 2022	SC 13G/A	FLGT / Fulgent Genetics Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us3596641098012622.txt us3596641098012622.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) FULGENT GENETICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 359664109 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate b
November 9, 2021	EX-99.1	September 30, Exhibit 99.1 Fulgent Genetics Reports Third Quarter Financial Results ? Revenue grows 124% year-over-year to $227.9 million ? Core Revenue grows 292% year-over-year to $40.1 million ? Raises Full Year Revenue guidance to $930 million from $800 million, given recent strength in core and COVID-19 business TEMPLE CITY, CA, November 9, 2021 ?Fulgent Genetics, Inc. (NASDAQ: FLGT) (?Fulgent Genetics? or
November 9, 2021	EX-99.2	Mission, Core Values, and Strategy 3 Mission Develop flexible and affordable genomic testing that improves the everyday lives of those around us Core Values Innovation Customer service and commitment Quality Efficiency Strategy Leverage our proprieta Founded in 2011 \| Located in Los Angeles, CA \| NASDAQ:FLGT 1 Exhibit 99.2 November 2021 Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the ?Company?) about future events based on current views and assum
November 9, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ff UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC.
November 9, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission F
August 10, 2021	EX-10.1	Restructuring Agreement of Fujian Fujun Gene Biotech Co., Ltd. Exhibit 10.1 Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed. Restructuring Agreement of Fujian Fujun Gene Biotech Co., Ltd This Restructuring Agreement of Fujian Fu
August 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC.
August 9, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 FULGENT GENETICS, ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil
August 9, 2021	EX-99.1	June 30, Exhibit 99.1 Fulgent Genetics Reports Second Quarter Financial Results ? Revenue grows 790% year over year to $153.6 million ? Core Revenue grows 296% year over year to $25.7 million ? Announces acquisition of CSI Laboratories ? Announces commercial agreement with Helio Health through strategic investment ? Announces incremental controlling investment in Chinese Joint Venture entity, FF Gene Biote
August 9, 2021	EX-99.2	Mission, Core Values, and Strategy Mission Develop flexible and affordable genomic testing that improves the everyday lives of those around us Core Values Innovation Customer service and commitment Quality Efficiency Strategy Leverage our proprietary Founded in 2011 \| Located in Los Angeles, CA \| NASDAQ:FLGT 1 Exhibit 99.2 Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the ?Company?) about future events based on current views and assumptions. Exampl
July 12, 2021	SC 13G/A	FLGT / Fulgent Genetics Inc / BlackRock Inc. Passive Investment us3596641098071021.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) FULGENT GENETICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 359664109 - (CUSIP Number) June 30, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w
May 20, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File Nu
May 7, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC.
May 7, 2021	EX-10.1	Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.1 FULGENT GENETICS, INC. AMENDED AND RESTATED DIRECTOR COMPENSATION PROGRAM This Amended and Restated Director Compensation Program (this ?Program?) sets forth the compensation payable to directors of Fulgent Genetics, Inc., a Delaware corporation (the ?Company?), as consideration for their service as directors of the Company. This Program does not constitute a legally binding contract
May 6, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File Num
May 6, 2021	EX-99.1	March 31, Exhibit 99.1 Fulgent Genetics Reports Record First Quarter Financial Results First Quarter 2021 Results: ? Record Revenue of $359.4 million, growing more than 4,500% year-over-year ? Record Billable tests delivered approximately 3.8 million, or 290 times the volume of first quarter of 2020 ? Gross Margin improved approximately 32 percentage points year-over-year ? NGS Revenue grew 115% year-over-y
April 1, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Defin
April 1, 2021	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Defin
March 8, 2021	EX-10.36	Commercial Lease Addendum, dated February 1, 2021, by and between E & E Plaza LLC and Fulgent Genetics, Inc. Exhibit 10.36 COMMERCIAL LEASE ADDENDUM #1 This is addendum to the Commercial Lease Agreement signed on February 1, 2018 by E & E Plaza LLC ("Lessor") and Fulgent Therapeutics LLC ("Lessee"). This document modifies the Commercial Lease Agreement as described below. 1. The Lessor agrees to extend this lease for Two (2) Years, starting on February 1, 2021 and expiring on January 31, 2023. 2. For thi
March 8, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37894 FULGENT GENETIC
March 8, 2021	EX-10.35	Commercial Lease Assignment & Assumption, dated January 11, 2021 by and between Ten-Voss Ltd., Medscan Laboratories, Inc. and Fulgent Genetics, Inc. Exhibit 10.35 LEASE ASSIGNMENT & ASSUMPTION WHEREAS, by Service Center Lease Agreement (the "Lease") dated June 17, 2020, TEN-VOSS, LTD, "Landlord" or ?Lessor?, leased MEDSCAN LABORATORIES INC. hereinafter ?Tenant? or ?Lessee?, those certain premises at 8560 Katy Freeway, Suite 200, Houston, Texas 77024. WHEREAS, the Lease Term commenced September 1, 2020 and expires November 30, 2023 in accordanc
March 8, 2021	EX-10.37	Employment Agreement, dated March 8, 2021, by and among Fulgent Therapeutics, LLC, Fulgent Genetics, Inc. and Jian Xie. Exhibit 10.37 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?), dated March 8, 2021, is by and among Fulgent Therapeutics LLC, a California limited liability company (the ?Company?), Fulgent Genetics, Inc., a Delaware corporation (?HoldCo?) and Jian Xie (?Executive?). 1. POSITION AND RESPONSIBILITIES (a) Position. Executive is employed by the Company to render services to the Compa
March 8, 2021	EX-10.34	Commercial Sublease Agreement, dated July 1st, 2020, between Medscan Laboratories Inc. and Fulgent Genetics, Inc.; Commercial Lease Agreement, dated June 17, 2020, by and between Medscan Laboratories Inc. and Ten-Voss Ltd. Exhibit 10.34 SUBLEASE AGREEMENT This SUBLEASE AGREEMENT (this ?Sublease?) is entered into as of July 1st, 2020 (the ?Effective Date?), between Medscan Laboratory (?Tenant?) and Fulgent Genetics (?Subtenant?), with reference to the following: A.Ten Voss, LTD, a Texas Limited Partnership, (?Landlord?) as Landlord, and Tenant with respect to that certain Lease Agreement dated June 17th, 2020 (the ?O
March 8, 2021	EX-10.38	Severance Agreement, dated March 8, 2021, by and among Fulgent Therapeutics LLC, Fulgent Genetics, Inc. and Jian Xie. Exhibit 10.38 SEVERANCE AGREEMENT This SEVERANCE AGREEMENT (the ?Agreement?), dated March 8, 2021, is by and among Fulgent Therapeutics LLC, a California limited liability company (the ?Company?), Fulgent Genetics, Inc., a Delaware corporation (?HoldCo?) and Jian Xie (?Executive?). WHEREAS, Executive is employed by the Company to render services to the Company in the position of Chief Operating Of
March 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File N
March 4, 2021	EX-99.1	December 31, EX-99.1 2 flgt-ex9916.htm EX-99.1 Exhibit 99.1 Fulgent Genetics Reports Record Fourth Quarter and Full Year 2020 Financial Results Fourth Quarter 2020 Results: • Record Revenue of $295.0 million, growing more than 3,400% year-over-year • Record Billable tests delivered approximately 3.2 million, approximately 230 times the volume of fourth quarter of 2019 • Gross Margin improved over 8 percentage
February 5, 2021	8-K	Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2021 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission
February 2, 2021	SC 13G	SC 13G us3596641098020221.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) FULGENT GENETICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 359664109 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t
December 22, 2020	SC 13D	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. __)* Fulgent Genetics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Se UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Fulgent Genetics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 359664109 (CUSIP Number) Ming Hsieh c/o Fulgent Genetics, Inc. 4978 Santa Anita Avenue Temple City, California 91780 (626) 350-0537 (Name, Add
December 22, 2020	EX-1	Joint Filing Agreement, dated as of December 22, 2020, by and among Mr. Hsieh and the Trust Exhibit 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements.
November 23, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 flgt-8k20201123.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2020 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of
November 23, 2020	EX-99.1	Fulgent Genetics Announces Increase to Full Year 2020 Guidance to $300 million Exhibit 99.1 Fulgent Genetics Announces Increase to Full Year 2020 Guidance to $300 million TEMPLE CITY, California – November 23, 2020 – Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it has updated its revenue guidance for the full year 2020
November 20, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K FOR NOVEMBER 2020 ATM UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2020 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commissio
November 20, 2020	EX-1.1	Equity Distribution Agreement, dated as of November 20, 2020, by and between Fulgent Genetics, Inc. and Piper Sandler & Co., BTIG, LLC, and Oppenheimer & Co. Inc. Exhibit 1.1 FULGENT GENETICS, INC. EQUITY DISTRIBUTION AGREEMENT November 20, 2020 PIPER SANDLER & CO. BTIG, LLC OPPENHEIMER & CO. INC. c/o Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 c/o BTIG, LLC 65 East 55th Street New York, NY 10022 c/o Oppenheimer & Co. Inc. 85 Broad Street, 26th Floor New York, NY 10004 Ladies and Gentlemen: As further set forth in
November 20, 2020	424B5	PROSPECTUS SUPPLEMENT (to Prospectus dated August 12, 2020) Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-239964 PROSPECTUS SUPPLEMENT (to Prospectus dated August 12, 2020) $175,000,000 Common Stock We have entered into an equity distribution agreement, dated November 20, 2020, or the Equity Distribution Agreement, with Piper Sandler & Co., or Piper Sandler, BTIG, LLC, or BTIG, and Oppenheimer & Co. Inc., or Oppenheimer, and collectively with Piper
November 9, 2020	EX-10.2	Aircraft Purchase Agreement, dated August 18, 2020, by and between ServiceMaster Acceptance Corporation and the Company Exhibit 10.2 AIRCRAFT PURCHASE AGREEMENT between ServiceMaster Acceptance Corporation as Seller, and Fulgent Genetics, Inc. as Purchaser, involving that certain Cessna Aircraft Company, model 680 aircraft, bearing manufacturer Serial Number 680-0255 and United States Registration Number N860SM AIRCRAFT PURCHASE AGREEMENT This AIRCRAFT PURCHASE AGREEMENT dated as of August 18, 2020 (this “Agreement
November 9, 2020	EX-99.1	September 30, Exhibit 99.1 Fulgent Genetics Reports Record Third Quarter 2020 Financial Results and Raises Full Year 2020 Revenue Guidance by $100 Million Third Quarter 2020 Results: • Record Revenue of $101.7 million, growing more than 880% year-over-year • Record Billable tests delivered approximately 1.04 million, growing more than 4,800% year-over-year • Gross Margin improved approximately 19 percentage poi
November 9, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil
November 9, 2020	10-Q	Quarterly Report - 10-Q 10-Q 1 flgt-10q20200930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi
October 21, 2020	8-K	Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets - 8-K FOR EL MONTE PROPERTY CLOSE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2020 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission
October 21, 2020	EX-2.1	Agreement for Purchase and Sale of Property, dated July 23, 2020 EX-2.1 2 flgt-ex216.htm EX-2.1 Exhibit 2.1 AGREEMENT FOR PURCHASE AND SALE OF PROPERTY and JOINT ESCROW INSTRUCTIONS By and Between 4401 Santa Anita Corporation, a California corporation, as Seller And Fulgent Genetics, Inc., a Delaware Corporation, as Buyer AGREEMENT FOR PURCHASE AND SALE OF REAL PROPERTY AND JOINT ESCROW INSTRUCTIONS THIS AGREEMENT FOR PURCHASE AND SALE OF REAL PROPERTY AND JOIN
September 25, 2020	424B5	PROSPECTUS SUPPLEMENT (to Prospectus dated August 12, 2020) Common Stock 424B5 1 flgt-424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-239964 PROSPECTUS SUPPLEMENT (to Prospectus dated August 12, 2020) $125,000,000 Common Stock We have entered into an equity distribution agreement, dated September 24, 2020, or the Equity Distribution Agreement, with Piper Sandler & Co., or Piper Sandler, relating to shares of our common stock, par value $0.0001 per
September 25, 2020	EX-1.1	Equity Distribution Agreement, dated as of September 24, 2020, by and between Fulgent Genetics, Inc. and Piper Sandler & Co. EX-1.1 2 flgt-ex116.htm EX-1.1 Exhibit 1.1 FULGENT GENETICS, INC. EQUITY DISTRIBUTION AGREEMENT September 24, 2020 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Fulgent Genetics, Inc., a company organized under the laws of the State of Delaware (the “Company”), proposes to issu
September 25, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 flgt-8k20200924.htm 8-K FOR 2020 ATM UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2020 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37894 81-2621304 (State or oth
September 22, 2020	S-8	- S-8 As filed with the Securities and Exchange Commission on September 22, 2020 Registration No.
September 18, 2020	EX-10.1	Fulgent Genetics, Inc. Amended and Restated 2016 Omnibus Incentive Plan EX-10.1 2 flgt-ex1016.htm EX-10.1 Exhibit 10.1 FULGENT GENETICS, INC. AMENDED AND RESTATED 2016 OMNIBUS INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. 2. Definitions. The following definitions shall
September 18, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2020 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission F
September 17, 2020	SC 13D/A	FLGT / Fulgent Genetics, Inc. / Gao Hanlin - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Fulgent Genetics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 359664109 (CUSIP Number) Han Lin Gao c/o Fulgent Genetics, Inc. 4978 Santa Anita Avenue Temple City, California 91780 (626) 350-0537 (Name, Ad
August 31, 2020	DEF 14A	August 31, 2020 DEF 14A 1 flgt-def14a20200917.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only
August 21, 2020	PRE 14A	- PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Defin
August 21, 2020	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2020 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission
August 7, 2020	CORRESP	- CORRESP 1 filename1.htm FULGENT GENETICS, iNC. 4978 Santa Anita Avenue Temple City, CA 91780 August 7, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Gabor RE: Fulgent Genetics, Inc. Registration Statement on Form S-3 Filed July 21, 2020, as amended on August 5, 2020 File No. 333-239964 Re
August 5, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 flgt-8k20200804.htm 8-K FOR ATM UPSIZE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37894 81-2621304 (State or other
August 5, 2020	EX-1.1	Amendment No. 1 to Equity Distribution Agreement, dated August 4, 2020, by and between Fulgent Genetics, Inc. and Piper Sandler & Co. Exhibit 1.1 AMENDMENT NO. 1 TO EQUITY DISTRIBUTION AGREEMENT August 4, 2020 Ladies and Gentlemen: Fulgent Genetics, Inc. (the “Company”) and Piper Sandler & Co. (formerly known as Piper Jaffray & Co.) (the “Agent”) are parties to that certain Equity Distribution Agreement dated August 30, 2019 (the “Original Agreement”). All capitalized terms used but not defined in this Amendment No. 1 to the Ori
August 5, 2020	10-Q	Quarterly Report - 10-Q 10-Q 1 flgt-10q20200630.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fi
August 5, 2020	424B5	PROSPECTUS SUPPLEMENT (to Prospectus dated August 23, 2019) Common Stock 424B5 1 flgt-424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-233227 PROSPECTUS SUPPLEMENT (to Prospectus dated August 23, 2019) $44,920,000 Common Stock We have entered into an equity distribution agreement, dated August 30, 2019 with Piper Sandler & Co., or Piper Sandler, as amended on August 4, 2020, or the Equity Distribution Agreement, relating to shares of our common sto
August 5, 2020	S-3/A	- S-3/A As filed with the Securities and Exchange Commission on August 5, 2020 Registration No.
August 5, 2020	CORRESP	- 3580 Carmel Mountain Road Suite 300 San Diego, CA 92130 858 314 1500 mintz.com August 5, 2020 VIA EDGAR & OVERNIGHT MAIL Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Office of Life Sciences Re: Fulgent Genetics, Inc. Registration Statement on Form S-3 Filed July 21, 2020 File No. 333-239964 (the “Registration Statement”) La
August 4, 2020	EX-99.1	June 30, Exhibit 99.1 Fulgent Genetics Reports Record Second Quarter 2020 Financial Results Second Quarter 2020 Results: • Record Revenue of $17.3 million, growing 105% year-over-year • Record Billable tests delivered total 180,513, growing 1003% year-over-year • Gross Margin improved approximately 8 percentage points from Q1 2020; cost per test improved approximately 81% year-over-year • Record GAAP earni
August 4, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File
July 31, 2020	LETTER	LETTER United States securities and exchange commission logo July 31, 2020 Paul Kim Chief Financial Officer Fulgent Genetics, Inc.
July 31, 2020	TEXT-EXTRACT	- United States securities and exchange commission logo July 31, 2020 Paul Kim Chief Financial Officer Fulgent Genetics, Inc.
July 27, 2020	8-K	Entry into a Material Definitive Agreement 8-K 1 flgt-8k20200717.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2020 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of
July 21, 2020	S-3	Power of Attorney (included on the signature page to this registration statement as filed on July 20, 2020) S-3 1 flgt-s3.htm S-3 As filed with the Securities and Exchange Commission on July 20, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FULGENT GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 81-2621304 (State or other jurisdiction of incorporation) (I.
July 21, 2020	EX-4.4	Form of Senior Indenture Exhibit 4.4 FULGENT GENETICS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act Section of of 1939, as Amended Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.0
July 21, 2020	EX-4.5	Form of Subordinated Indenture Exhibit 4.5 FULGENT GENETICS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(
June 12, 2020	SC 13G/A	FLGT / Fulgent Genetics, Inc. / Xi Long USA, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2-Exit Filing)* FULGENT GENETICS, INC. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 359664109 (CUSIP Number of Class of Securities) June 8, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate b
June 2, 2020	SC 13G/A	FLGT / Fulgent Genetics, Inc. / Xi Long USA, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* FULGENT GENETICS, INC. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 359664109 (CUSIP Number of Class of Securities) May 19, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
May 27, 2020	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 flgt-8k20200527.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2020 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of inco
May 6, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC.
May 6, 2020	424B5	Fulgent Genetics, Inc. Up to $30,000,000 Common Stock 424B5 1 flgt-424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-233227 Prospectus Supplement (To Prospectus Dated August 23, 2019) Fulgent Genetics, Inc. Up to $30,000,000 Common Stock We previously entered into an equity distribution agreement, dated August 30, 2019 (the “Equity Distribution Agreement”) with Piper Sandler & Co. (“Piper Sandler”) pursuant to which we may offer a
May 4, 2020	EX-99.1	March 31, Exhibit 99.1 Fulgent Genetics Reports First Quarter 2020 Financial Results First Quarter 2020 Results: • Revenue totals $7.8 million, growing 44% year over year • Billable tests delivered total 13,163, growing 75% year over year • Gross Margin improves approximately 3 percentage points year over year; cost per test improves approximately 22% year over year • GAAP loss of $2.0 million, or $0.09 per
May 4, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 flgt-8k20200504.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2020 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incor

FLGT / Fulgent Genetics, Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?

Other Listings